Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

dd9437f5f8e96470e008880110a272e19f78626fd6c12a22ed96d87a73b90b15

9c28be1f405578ee5bc06cb2478e9b45b6803a0705794585024865efc015ae90

06e3d65da6a2b3e0de4308cf51678b20923c3be8c144649858f52f6a728d175e

LUMRYZ

- Caremark

- Accredo

- Optum

Bloxiverz

Vazculep

Akovaz

Other

Noctiva

License Revenue

Total Revenue

44bc94ec6c3adb320c9079c48d2c6bc322f8244d2748b80f53972124f752ae6d

United States

France

Ireland

386df441ca954ae99cf0e0749f78aa610b34c8f1315c1bf3e530acafde0c8986

Net Product Revenue (USD, thousands)

Cost of Products Sold (USD, thousands)

Gross Profit (USD, thousands)

Research and Development Expenses (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Total Operating Expense (USD, thousands)

Operating Loss (USD, thousands)

Investment and Other Income, Net (USD, thousands)

Interest Expense (USD, thousands)

Loss on Extinguishment of Debt (USD, thousands)

Loss Before Income Taxes (USD, thousands)

Income Tax Provision (Benefit) (USD, thousands)

Net Loss (USD, thousands)

Net Loss per Share - Basic (USD)

Net Loss per Share - Diluted (USD)

Weighted Average Number of Shares Outstanding - Basic (thousands)

Weighted Average Number of Shares Outstanding - Diluted (thousands)

Restructuring Expense (Income) (USD, thousands)

Total Operating Expenses (USD, thousands)

Investment and Other Income (Expense), Net (USD, thousands)

Income Tax (Benefit) Provision (USD, thousands)

8948e3aaaa9b3769804cb58a47fcdbd705cabc815946957edcbe010d3381a27d

17f34e261601b076dccf623431544da564f817d20d3f22739048610e13f33626

The significant revenue jump in Q4 2023 was driven by the **commercial launch of LUMRYZ**. This launch, which followed the FDA approval on **May 1, 2023**, led to the recognition of **$19.5 million** in net product revenue, a dramatic increase compared to previous periods. Key factors included the **successful launch of LUMRYZ**, strong **patient uptake** with over **1,000 new patients** initiating therapy and more than **1,900 patients** enrolling in support services, as well as improved **market access** through contracts with major PBM-owned GPOs.  **[0001104659-24-030226_tm247844d1_ex99-1.htm:1]** **[0001104659-24-030226_tm247844d1_ex99-1.htm:5]** **[0001104659-24-002062_tm242268d1_ex99-1.htm:0]** 

What drove the significant revenue jump in Q4 2023?

The dramatic reduction in **operating loss** in Q3 2024 was primarily driven by a **substantial increase in net product revenue** from the successful commercial launch of **LUMRYZ**, which boosted revenue significantly, and by a corresponding **rise in gross profit**. Additionally, although there was a slight increase in operating expenses, it was comparatively moderate and did not offset the gains from increased revenue and gross profit, resulting in a significant overall improvement in operating loss.  **[0001012477-24-000021_avdl-20240930.htm:4]** **[0001012477-24-000021_avdl-20240930.htm:32]** **[0001012477-24-000021_avdl-20240930.htm:30]** 

What contributed to the dramatic reduction in operating loss in Q3 2024?

Avadel Pharmaceuticals nearly broke even on a per-share basis in Q3 2024 because the company experienced **strong revenue growth** and **substantial cost improvements**. The commercial launch of **LUMRYZ** boosted net product revenue from **$7.0 million** in Q3 2023 to **$50.0 million** in Q3 2024, which, along with a rise in gross profit, led to a sharp reduction in the overall net loss—from **$(36.3) million** to **$(2.6) million**. Additionally, the increase in the weighted average number of shares outstanding diluted the loss per share, narrowing the **Net Loss per Share – Basic** from **$(0.41)** to **$(0.03)**, essentially bringing it near a break-even point.  **[0001012477-24-000021_avdl-20240930.htm:4]** **[0001012477-24-000021_avdl-20240930.htm:32]** **[0001012477-24-000021_avdl-20240930.htm:16]** 

How did the company nearly break even on a per-share basis in Q3 2024?

The sharp decrease in net loss in Q3 2024 was primarily driven by **a significant increase in net product revenue** due to the commercial launch of **LUMRYZ**, which boosted overall sales, **improvements in gross profit** resulting from both higher revenue and enhanced cost efficiencies, and a **notable reduction in operating loss** (with operating losses decreasing from over **$(35,000)** to approximately **$(327)**). Additionally, the absence of the **$13,129 loss on extinguishment of debt** seen in the previous period further contributed to the improved net loss, while increased patient uptake for LUMRYZ supported revenue growth overall.  **[0001012477-24-000021_avdl-20240930.htm:32]** **[0001012477-24-000021_avdl-20240930.htm:4]** **[0001104659-24-116323_tm2427974d1_ex99-1.htm:0]** 

What factors drove the sharp decrease in net loss in Q3 2024?

8382819f65253279da13e8517c7ff18c70c0ee5fe87d9443e2814e0d806b1070

**Avadel Pharmaceuticals experienced a sharp drop in cash and cash equivalents in Q4 2023 primarily because the company used **$26 million** in net cash for operations and repaid **$22 million** on its convertible notes, which together resulted in a total reduction of **$48 million** during the quarter.  **[AVDL_3376298_4]** **

What drove the sharp drop in Cash and cash equivalents in Q4 2023?

Based on the provided documents, there isn’t any explicit explanation for a significant decline in total assets in Q4 2023 compared to Q3 2023. One document discusses the reasons behind the increase in total assets from **$132,785 thousand** as of December 31, 2022, to **$164,698 thousand** as of December 31, 2023—including increases in marketable securities, accounts receivable and inventories, and prepaid expenses and other current assets.  **[0001104659-24-030226_tm247844d1_ex99-1.htm:6]** **[0001012477-24-000008_avdl-20231231.htm:121]**  However, no details are given regarding the decline from the Q3 total assets of **203,100 thousand** to the Q4 total assets of **164,698 thousand**.  **[0001012477-23-000023_avdl-20230930.htm:5]** **[0001012477-24-000021_avdl-20240930.htm:5]** 

Why did Total assets decline significantly in Q4 2023?

The documents do not provide any specific explanation for why Q1 2024’s total liabilities of **$89,515 thousand** are roughly half of Q1 2023’s **$178,905 thousand**. The only explanation available discusses changes within Q1 2024—namely increases in accounts payable, accrued expenses, and the royalty financing obligation between December 31, 2023, and March 31, 2024—not a reduction compared to Q1 2023.  **[0001012477-23-000012_avdl-20230331.htm:5]** **[0001012477-24-000012_avdl-20240331.htm:5]** 

What explains the halving of Total liabilities in Q1 2024?

b92c6c7de6406d57827844ede7e2522464a7db5290f9f64e88dd9c32cbdd62d7

Avadel Pharmaceuticals PLC (AVDL)

Financials